PT3495358T - Compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifn-alfa - Google Patents
Compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifn-alfaInfo
- Publication number
- PT3495358T PT3495358T PT181975509T PT18197550T PT3495358T PT 3495358 T PT3495358 T PT 3495358T PT 181975509 T PT181975509 T PT 181975509T PT 18197550 T PT18197550 T PT 18197550T PT 3495358 T PT3495358 T PT 3495358T
- Authority
- PT
- Portugal
- Prior art keywords
- modulators
- amide
- substituted heterocyclic
- heterocyclic compounds
- compounds useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723840P | 2012-11-08 | 2012-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3495358T true PT3495358T (pt) | 2022-06-02 |
Family
ID=49876960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT181975509T PT3495358T (pt) | 2012-11-08 | 2013-11-07 | Compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifn-alfa |
| PT13811640T PT2922846T (pt) | 2012-11-08 | 2013-11-07 | Compostos heterocíclicos substituídos por amida úteis como moduladores de il-12, il-23 e/ou ie'n-alfa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT13811640T PT2922846T (pt) | 2012-11-08 | 2013-11-07 | Compostos heterocíclicos substituídos por amida úteis como moduladores de il-12, il-23 e/ou ie'n-alfa |
Country Status (40)
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4071144A1 (en) * | 2012-11-08 | 2022-10-12 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| EA028052B1 (ru) | 2012-11-08 | 2017-10-31 | Бристол-Майерс Сквибб Компани | АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| JP6458038B2 (ja) | 2013-12-10 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| US9834548B2 (en) | 2014-02-14 | 2017-12-05 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as JAK inhibitors |
| PH12018501019B1 (en) | 2015-11-26 | 2023-03-15 | Novartis Ag | Diamino pyridine derivatives |
| ES2930198T3 (es) | 2016-10-14 | 2022-12-07 | Nimbus Lakshmi Inc | Inhibidores de TYK2 y usos de los mismos |
| IL266109B2 (en) | 2016-10-21 | 2025-05-01 | Nimbus Lakshmi Inc | Tyk2 inhibitors and uses thereof |
| EP3555111B1 (en) | 2016-12-13 | 2022-01-26 | Bristol-Myers Squibb Company | Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| TWI868528B (zh) | 2017-03-08 | 2025-01-01 | 日商武田藥品工業股份有限公司 | Ｔｙｋ２抑制劑之生產方法 |
| CA3058209A1 (en) * | 2017-03-30 | 2018-10-04 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
| MX2020005210A (es) * | 2017-11-21 | 2020-08-20 | Bristol Myers Squibb Co | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona. |
| WO2019178079A1 (en) | 2018-03-12 | 2019-09-19 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| ES2944733T3 (es) * | 2018-03-22 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos heterocíclicos que comprenden piridina, útiles como moduladores de las respuestas a IL-12, IL-23 y/o IFN alfa |
| CN118994118A (zh) | 2018-05-31 | 2024-11-22 | 百时美施贵宝公司 | 化合物的结晶形式 |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| CA3115088A1 (en) | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| KR102850357B1 (ko) * | 2018-10-22 | 2025-08-27 | 알루미스 인크. | Tyk2 억제제 및 이의 용도 |
| BR112021007861A2 (pt) * | 2018-10-30 | 2021-08-03 | Bristol-Myers Squibb Pharma Company | compostos heterocíclicos substituídos por amida |
| JP7530360B2 (ja) | 2018-11-30 | 2024-08-07 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| AU2020212001A1 (en) | 2019-01-23 | 2021-07-22 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| JP7652697B2 (ja) * | 2019-01-28 | 2025-03-27 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ピリダジン系誘導体阻害剤、その製造方法及び使用 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| SG11202108162SA (en) * | 2019-01-30 | 2021-08-30 | Bristol Myers Squibb Co | Amide-disubstituted pyridine or pyridazine compounds |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| JP2022537877A (ja) | 2019-04-30 | 2022-08-31 | セルジーン コーポレイション | アプレミラストおよびｔｙｋ２阻害剤を含む併用療法 |
| CN114174284A (zh) * | 2019-06-12 | 2022-03-11 | 百时美施贵宝公司 | 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的结晶盐形式 |
| JP7618642B2 (ja) * | 2019-07-16 | 2025-01-21 | ブリストル－マイヤーズ スクイブ カンパニー | インターロイキンの調節におけるプロドラッグ |
| KR20220042159A (ko) | 2019-08-01 | 2022-04-04 | 인테그랄 바이오사이언스 피브이티. 엘티디. | 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도 |
| US12215105B2 (en) | 2019-09-13 | 2025-02-04 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| AU2020349524A1 (en) | 2019-09-18 | 2022-03-31 | Bristol-Myers Squibb Company | Dosage forms for Tyk2 inhibitors |
| WO2021129467A1 (zh) * | 2019-12-27 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种bms-986165晶型及其制备方法和用途 |
| WO2021143430A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型及其制备方法和用途 |
| WO2021143498A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| WO2021170046A1 (en) * | 2020-02-26 | 2021-09-02 | Beigene, Ltd. | Tyk-2 inhibitor |
| DK4038063T3 (da) * | 2020-03-11 | 2024-05-21 | Beijing Innocare Pharma Tech Co Ltd | Heterocykliske forbindelser til inhibering af tyk2-aktiviteter |
| WO2021204626A1 (en) * | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| CN113563309B (zh) * | 2020-04-28 | 2024-12-13 | 浙江海正药业股份有限公司 | 吡啶类衍生物及其制备方法和用途 |
| US12479831B2 (en) * | 2020-04-28 | 2025-11-25 | Bristol-Myers Squibb Company | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators |
| CN113735836B (zh) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | 哒嗪类化合物及其应用 |
| CN113735837B (zh) * | 2020-05-28 | 2023-09-01 | 江苏先声药业有限公司 | 哒嗪类化合物及其用途 |
| CN113773262B (zh) * | 2020-06-09 | 2024-08-09 | 江苏先声药业有限公司 | 哒嗪类化合物 |
| CN115715288B (zh) | 2020-06-22 | 2025-11-25 | 百济神州有限公司 | Tyk-2抑制剂 |
| CA3186000A1 (en) * | 2020-07-24 | 2022-01-27 | Shanghai Hansoh Biomedical Co., Ltd. | Crystal form of pyridazine derivative free base, and preparation method therefor and use thereof |
| CN113968846A (zh) * | 2020-07-24 | 2022-01-25 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物的盐、晶型及其制备方法和应用 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| WO2022021684A1 (zh) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型csv及其制备方法和用途 |
| CN114057651B (zh) * | 2020-07-31 | 2025-05-27 | 正大天晴药业集团股份有限公司 | 含酰胺基的tyk2抑制剂化合物 |
| CN116472044A (zh) | 2020-09-18 | 2023-07-21 | 百时美施贵宝公司 | 包含可溶胀核芯的Tyk2抑制剂的剂型 |
| CN116615200B (zh) * | 2020-10-20 | 2025-04-29 | 杭州领业医药科技有限公司 | 哒嗪衍生物的晶型 |
| US12331046B2 (en) | 2020-10-23 | 2025-06-17 | Nimbus Clotho, Inc. | CTPS1 inhibitors and uses thereof |
| CN120887875A (zh) * | 2020-11-12 | 2025-11-04 | 上海睿跃生物科技有限公司 | 酪氨酸激酶2(tyk2)降解化合物和使用方法 |
| WO2022105771A1 (zh) * | 2020-11-17 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类衍生物、其制备方法及其在医药上的应用 |
| CN116547276A (zh) * | 2020-12-08 | 2023-08-04 | 正大天晴药业集团股份有限公司 | 含酰胺基和杂环烷基的tyk2抑制剂化合物 |
| EP4267565A4 (en) | 2020-12-22 | 2025-01-08 | InventisBio Co., Ltd. | HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF |
| KR20230137962A (ko) | 2021-01-29 | 2023-10-05 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태 |
| WO2022167457A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| CN114907326B (zh) * | 2021-02-06 | 2025-02-18 | 正大天晴药业集团股份有限公司 | 含酰胺基和联环的tyk2抑制剂化合物 |
| TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途 |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| MX2023009685A (es) | 2021-02-19 | 2023-10-30 | Sudo Biosciences Ltd | Inhibidores de tyk2 y sus usos. |
| BR112023016614A2 (pt) | 2021-02-19 | 2023-11-07 | Sudo Biosciences Ltd | Inibidores de tyk2 e usos dos mesmos |
| CN117295737A (zh) | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| US20240246944A1 (en) | 2021-03-16 | 2024-07-25 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| KR20230163469A (ko) | 2021-03-29 | 2023-11-30 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| US20240182429A1 (en) * | 2021-03-30 | 2024-06-06 | Zhejiang Wenda Pharma Technology Ltd. | Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use |
| CN115197196B (zh) * | 2021-04-06 | 2024-06-18 | 扬子江药业集团有限公司 | Tyk2抑制剂及其用途 |
| MX2023011933A (es) | 2021-04-09 | 2024-01-05 | Nimbus Clio Inc | Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos. |
| US20240382477A1 (en) | 2021-05-04 | 2024-11-21 | Shanghai Zheye Biotechnology Co. Ltd. | Nitrogen-containing heterocyclic pyridine compound |
| EP4337655A1 (en) * | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240008337A (ko) | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| JP2024518556A (ja) * | 2021-05-14 | 2024-05-01 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| EP4337656A1 (en) * | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| WO2022253335A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 含磺酰基的芳基类化合物及其应用 |
| CN115466289A (zh) * | 2021-06-11 | 2022-12-13 | 爱科诺生物医药(香港)有限公司 | 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用 |
| CA3223641A1 (en) * | 2021-06-22 | 2022-12-29 | Wenyuan Qian | Sulfoximine compound and use thereof |
| JP2024535865A (ja) * | 2021-07-15 | 2024-10-02 | メッドシャイン ディスカバリー インコーポレイテッド | 硫黄／リン含有アリール系化合物及びその使用 |
| EP4387968B1 (en) * | 2021-08-20 | 2025-11-12 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| WO2023027948A1 (en) * | 2021-08-21 | 2023-03-02 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| AU2022350509A1 (en) | 2021-09-23 | 2024-04-04 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| US20240390369A1 (en) | 2021-09-30 | 2024-11-28 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| JP2024539703A (ja) | 2021-10-28 | 2024-10-29 | ブリストル－マイヤーズ スクイブ カンパニー | デュークラバシチニブの局所製剤 |
| EP4441043A1 (en) | 2021-12-01 | 2024-10-09 | Teva Czech Industries s.r.o | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| KR20240120732A (ko) * | 2021-12-16 | 2024-08-07 | 링크 파마슈티컬스 컴퍼니 리미티드 | Tyk2 억제제, 이의 조성물 및 방법 |
| CN116283928A (zh) * | 2021-12-20 | 2023-06-23 | 艾立康药业股份有限公司 | 一种哒嗪类化合物、其制备方法和应用 |
| EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| CN116693449A (zh) * | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| WO2023231997A1 (zh) * | 2022-05-31 | 2023-12-07 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| CN117447411B (zh) * | 2022-07-18 | 2025-12-23 | 苏州鹏旭医药科技有限公司 | 一种杂环药物中间体的合成方法 |
| US20260035356A1 (en) | 2022-07-21 | 2026-02-05 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| CN120019047A (zh) | 2022-08-02 | 2025-05-16 | 里米诺生物科学有限公司 | 杂芳基甲酰胺和相关gpr84拮抗剂及其用途 |
| AU2023317742A1 (en) | 2022-08-02 | 2025-03-20 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
| TW202415650A (zh) | 2022-08-02 | 2024-04-16 | 英商利米那生物科技有限公司 | 芳基-三唑基及相關gpr84拮抗劑及其用途 |
| KR20250099236A (ko) * | 2022-11-08 | 2025-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| TW202430168A (zh) | 2022-12-16 | 2024-08-01 | 印度商阿蘭比克製藥有限公司 | Tyk2假激酶配體及其用途 |
| CN116284040B (zh) * | 2023-01-05 | 2024-05-28 | 华润医药研究院（深圳）有限公司 | 含氮杂环类化合物及其医药用途 |
| WO2024165000A1 (zh) * | 2023-02-07 | 2024-08-15 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| CN118724752B (zh) * | 2023-03-29 | 2025-11-28 | 重庆博腾制药科技股份有限公司 | 一种酪氨酸激酶抑制剂中间体、制备方法及其应用 |
| CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
| WO2024236491A1 (en) * | 2023-05-15 | 2024-11-21 | Glenmark Life Sciences Limited | Process for the preparation of deucravacitinib, and crystalline forms thereof |
| CN119080742A (zh) * | 2023-06-05 | 2024-12-06 | 甘莱制药有限公司 | 脂质合成的杂环调节剂的工业化制备 |
| WO2024257023A1 (en) | 2023-06-14 | 2024-12-19 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
| TW202529769A (zh) | 2023-09-21 | 2025-08-01 | 日商武田藥品工業股份有限公司 | Ｔｙｋ２抑制劑及其用途 |
| CN117447353B (zh) * | 2023-09-21 | 2025-12-30 | 爱斯特（成都）生物制药股份有限公司 | 一种氘可来昔替尼中间体的制备方法 |
| EP4538259A1 (en) | 2023-10-09 | 2025-04-16 | Farmhispania Group, S.L. | Processes for the preparation of deucravacitinib |
| WO2025131031A1 (zh) * | 2023-12-22 | 2025-06-26 | 上海奥博生物医药股份有限公司 | 一种TyK2抑制剂及其中间体的制备方法 |
| WO2025173029A1 (en) * | 2024-02-14 | 2025-08-21 | Natco Pharma Limited | An improved process for the preparation of deucravacitinib |
| WO2025186427A1 (en) | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
| CN118593504B (zh) * | 2024-06-03 | 2025-03-18 | 北京大学第三医院（北京大学第三临床医学院） | 氘可来昔替尼或其盐在制备pvns药物方面的新用途 |
| CN119059972B (zh) * | 2024-08-12 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种btk抑制剂吡托布鲁替尼的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2237430T3 (es) | 1999-06-09 | 2005-08-01 | Yamanouchi Pharmaceutical Co. Ltd. | Nuevos derivados carboxamida heterociclicos. |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| AU5108000A (en) * | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
| ZA200500480B (en) | 2002-07-15 | 2006-10-25 | Wyeth Corp | Methods and compositions for modulating T helper (TH) cell development and function |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| CA2793024A1 (en) | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
| AR082974A1 (es) | 2010-09-15 | 2013-01-23 | Hoffmann La Roche | Derivados de azabenzotiazol, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para tratar enfermedades inflamatorias |
| JP2013542966A (ja) | 2010-11-19 | 2013-11-28 | エフ．ホフマン−ラ ロシュ アーゲー | ピラゾロピリジンならびにｔｙｋ２阻害剤としてのピラゾロピリジン及びそれらの使用 |
| US9145414B2 (en) * | 2011-09-30 | 2015-09-29 | Taiho Pharmaceutical Co., Ltd. | 1,2,4-triazine-6-carboxamide derivative |
| JP6109192B2 (ja) * | 2012-01-10 | 2017-04-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピリダジンアミド化合物及びｓｙｋ阻害剤としてのそれらの使用 |
| US20130310387A1 (en) * | 2012-05-16 | 2013-11-21 | Novartis Ag | Monocyclic Heteroaryl Cycloalkyldiamine Derivatives |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| US10112928B2 (en) * | 2012-10-19 | 2018-10-30 | Hoffmann-La Roche Inc. | Inhibitors of SYK |
| EA028052B1 (ru) | 2012-11-08 | 2017-10-31 | Бристол-Майерс Сквибб Компани | АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα |
| EP4071144A1 (en) * | 2012-11-08 | 2022-10-12 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| JP6259463B2 (ja) | 2012-11-08 | 2018-01-10 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| CA3058209A1 (en) * | 2017-03-30 | 2018-10-04 | Bristol-Myers Squibb Company | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
-
2013
- 2013-11-07 EP EP22165094.8A patent/EP4071144A1/en active Pending
- 2013-11-07 MY MYPI2015701475A patent/MY175448A/en unknown
- 2013-11-07 TW TW102140572A patent/TWI605041B/zh active
- 2013-11-07 HU HUE18197550A patent/HUE059409T2/hu unknown
- 2013-11-07 UY UY0001035126A patent/UY35126A/es unknown
- 2013-11-07 US US14/441,183 patent/US9505748B2/en not_active Ceased
- 2013-11-07 ES ES18197550T patent/ES2914793T3/es active Active
- 2013-11-07 BR BR112015010102-0A patent/BR112015010102B1/pt active IP Right Grant
- 2013-11-07 CA CA2890981A patent/CA2890981C/en active Active
- 2013-11-07 HR HRP20220766TT patent/HRP20220766T1/hr unknown
- 2013-11-07 ES ES13811640T patent/ES2702148T3/es active Active
- 2013-11-07 DK DK13811640.5T patent/DK2922846T3/en active
- 2013-11-07 EA EA201590917A patent/EA028814B1/ru not_active IP Right Cessation
- 2013-11-07 PE PE2015000607A patent/PE20150944A1/es active IP Right Grant
- 2013-11-07 SG SG10201706897TA patent/SG10201706897TA/en unknown
- 2013-11-07 EP EP13811640.5A patent/EP2922846B1/en active Active
- 2013-11-07 WO PCT/US2013/068846 patent/WO2014074661A1/en not_active Ceased
- 2013-11-07 SM SM20190001T patent/SMT201900001T1/it unknown
- 2013-11-07 MY MYPI2020005025A patent/MY194668A/en unknown
- 2013-11-07 PL PL18197550T patent/PL3495358T3/pl unknown
- 2013-11-07 TR TR2018/20824T patent/TR201820824T4/tr unknown
- 2013-11-07 PL PL13811640T patent/PL2922846T3/pl unknown
- 2013-11-07 PT PT181975509T patent/PT3495358T/pt unknown
- 2013-11-07 LT LTEP18197550.9T patent/LT3495358T/lt unknown
- 2013-11-07 LT LTEP13811640.5T patent/LT2922846T/lt unknown
- 2013-11-07 AU AU2013341186A patent/AU2013341186B2/en active Active
- 2013-11-07 DK DK18197550.9T patent/DK3495358T3/da active
- 2013-11-07 RS RS20181428A patent/RS58187B1/sr unknown
- 2013-11-07 NZ NZ708859A patent/NZ708859A/en unknown
- 2013-11-07 SG SG10201706985UA patent/SG10201706985UA/en unknown
- 2013-11-07 US US16/201,653 patent/USRE47929E1/en active Active
- 2013-11-07 SI SI201331986T patent/SI3495358T1/sl unknown
- 2013-11-07 JP JP2015541883A patent/JP6407159B2/ja active Active
- 2013-11-07 RS RS20220589A patent/RS63328B1/sr unknown
- 2013-11-07 HU HUE13811640A patent/HUE041750T2/hu unknown
- 2013-11-07 SI SI201331219T patent/SI2922846T1/sl unknown
- 2013-11-07 AR ARP130104091A patent/AR094452A1/es active IP Right Grant
- 2013-11-07 EP EP18197550.9A patent/EP3495358B8/en active Active
- 2013-11-07 CN CN201380069692.9A patent/CN104884454B/zh active Active
- 2013-11-07 MY MYPI2022004735A patent/MY198262A/en unknown
- 2013-11-07 HR HRP20181937TT patent/HRP20181937T1/hr unknown
- 2013-11-07 SM SM20220258T patent/SMT202200258T1/it unknown
- 2013-11-07 MA MA38072A patent/MA38072A1/fr unknown
- 2013-11-07 SG SG11201503399XA patent/SG11201503399XA/en unknown
- 2013-11-07 KR KR1020157014694A patent/KR102195194B1/ko active Active
- 2013-11-07 PT PT13811640T patent/PT2922846T/pt unknown
- 2013-11-07 MX MX2015005731A patent/MX2015005731A/es active IP Right Grant
-
2015
- 2015-05-04 IL IL238610A patent/IL238610A0/en active IP Right Grant
- 2015-05-06 MX MX2020003156A patent/MX2020003156A/es unknown
- 2015-05-06 PH PH12015501004A patent/PH12015501004A1/en unknown
- 2015-05-07 CL CL2015001231A patent/CL2015001231A1/es unknown
- 2015-06-05 ZA ZA2015/04052A patent/ZA201504052B/en unknown
-
2016
- 2016-10-10 US US15/289,437 patent/US10000480B2/en active Active
-
2017
- 2017-02-17 AU AU2017201076A patent/AU2017201076B2/en active Active
-
2018
- 2018-05-15 US US15/979,770 patent/US10526321B2/en active Active
- 2018-05-16 JP JP2018094837A patent/JP6585231B2/ja active Active
- 2018-11-19 AU AU2018267545A patent/AU2018267545B2/en active Active
- 2018-12-14 CY CY20181101343T patent/CY1121188T1/el unknown
-
2019
- 2019-09-04 JP JP2019161215A patent/JP2020002157A/ja active Pending
- 2019-11-18 US US16/687,279 patent/US11021475B2/en active Active
-
2020
- 2020-06-15 AU AU2020203967A patent/AU2020203967B2/en active Active
-
2021
- 2021-04-29 US US17/244,938 patent/US20220356180A1/en not_active Abandoned
-
2022
- 2022-06-02 CY CY20221100391T patent/CY1125220T1/el unknown
-
2023
- 2023-07-24 NL NL301238C patent/NL301238I2/nl unknown
- 2023-07-27 CY CY2023017C patent/CY2023017I2/el unknown
- 2023-08-07 LU LU00313C patent/LUC00313I2/fr unknown
- 2023-08-10 HU HUS2300025C patent/HUS2300025I1/hu unknown
- 2023-08-14 FR FR23C1030C patent/FR23C1030I2/fr active Active
- 2023-08-23 LT LTPA2023523C patent/LTC2922846I2/lt unknown
- 2023-08-25 NO NO2023032C patent/NO2023032I1/no unknown
- 2023-08-28 FI FIC20230028C patent/FIC20230028I1/fi unknown
-
2024
- 2024-09-10 US US18/830,387 patent/US20250243193A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300025I1 (hu) | Amidszubsztituált heterociklikus vegyületek mint IL-12, IL-23 és/vagy IFN-ALFA modulátorai | |
| EP2922841B8 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| IL245448B (en) | Alkyl-amide substituted pyridyl compounds useful as modulators of responses to il-12, il-23, and/or ifnalpha | |
| SG11201501292UA (en) | Anxiolytic composition, formulation and method of use | |
| EP3054870A4 (en) | Compressed bone composition and methods of use thereof | |
| PL2988756T5 (pl) | Formulacja środka kontrastowego i powiązany sposób jego wytwarzania | |
| GB201301626D0 (en) | Composition comprising 15-OHEPA and methods of using the same | |
| WO2015081319A3 (en) | Activity enhancing curcumin compositions and methods of use | |
| EP2900916A4 (en) | STITCHING COLMATANT MATERIAL AND METHOD OF USE | |
| EP2900783A4 (en) | DEHYDRATED GEL COMPOSITIONS AND USE METHOD THEREFOR | |
| GB201307082D0 (en) | Pharmaceutical composition comprising 15-HETrE and methods of using the same | |
| ZA201502205B (en) | Ectoparasitic treatment method and composition | |
| AU2014318672B2 (en) | Recombinant microorganisms and methods of use thereof | |
| SMT201900406T1 (it) | Composti piridilici alchil-ammide-sostitidti utili come modulatori delle risposte di il-12, il-23 e/o ifn-alfa | |
| GB201207064D0 (en) | Pharmaceutical compositions comprising 15-hetre and methods of using the same | |
| AU2013902122A0 (en) | Ectoparasitic Treatment Method and Composition | |
| GB201310349D0 (en) | Composition and method of use thereof | |
| GB201301928D0 (en) | Composition and method of use thereof |